AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35488029 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers' BMI decrease at 12 months (among Māori participants)
Number of subjects: 0
Study 32855218 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated closed-loop oxygen administration
Number of subjects: 200
Study 32855218 — intervention group
Group type: COMPARATOR
Intervention: Standard manual oxygen administration
Number of subjects: 200
Study 36263182 — intervention group
Group type: EXPERIMENTAL
Intervention: JingYinGuBiao formula (JYGB)
Number of subjects: 885
Study 36263182 — intervention group
Group type: COMPARATOR
Intervention: TCM placebo
Number of subjects: 885
Study 32757636 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale
Number of subjects: 43
Study 32644867 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking with standard antifungal
Number of subjects: 20
Study 32644867 — intervention group
Group type: COMPARATOR
Intervention: Standard antifungal
Number of subjects: 20
Study 32497491 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir (800 mg given three times at 12 week intervals or 600 mg given five times, administered at one 4 week interval, and every 8 weeks thereafter)
Number of subjects: 177
Study 32497491 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable cabotegravir
Number of subjects: 177
Study 32497491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 34984805 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD) with a maximum of 20 E% from carbohydrates
Number of subjects: 71
Study 33530704 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 881
Study 33530704 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 881
Study 32917231 — intervention group
Group type: EXPERIMENTAL
Intervention: BDCPP
Number of subjects: 56
Study 32917231 — intervention group
Group type: EXPERIMENTAL
Intervention: DPHP
Number of subjects: 56
Study 32917231 — intervention group
Group type: EXPERIMENTAL
Intervention: BCEP
Number of subjects: 56
Study 34536136 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 32
Study 34536136 — intervention group
Group type: COMPARATOR
Intervention: Control (no EMD)
Number of subjects: 32
Study 36294019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Counselling (NC)
Number of subjects: 255
Study 36294019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition Counselling (NC) + Unconditional Cash Transfer (UCT)
Number of subjects: 255
Study 36294019 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 255
Study 33693782 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in physical activity (PA)
Number of subjects: 489
Study 33693782 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in adherence to the Mediterranean diet (MedDiet)
Number of subjects: 489
Study 35756958 — intervention group
Group type: EXPERIMENTAL
Intervention: Unaltered base attachment (UA)
Number of subjects: 6
Study 35756958 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom base attachment (CBA)
Number of subjects: 6
Study 35247960 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentorship (weekly telephone calls with trained mentors for 3 months)
Number of subjects: 200
Study 35247960 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 200
Study 34217844 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Astragalus Propinquus schischkin polysaccharides (1000 mg/kg)
Number of subjects: 5
Study 34217844 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Astragalus Propinquus schischkin polysaccharides (various dosages including 1000 mg/kg)
Number of subjects: 5
Study 32306935 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural group therapy (CBGT)
Number of subjects: 125
Study 32306935 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness‐based stress reduction (MBSR)
Number of subjects: 125
Study 35916003 — intervention group
Group type: EXPERIMENTAL
Intervention: Channel-cleaning ball brush (BB)
Number of subjects: 114
Study 35916003 — intervention group
Group type: COMPARATOR
Intervention: Conventional brush (CB)
Number of subjects: 114
Study 32711724 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised haemodynamic management targeting baseline cardiac index
Number of subjects: 188
Study 32711724 — intervention group
Group type: COMPARATOR
Intervention: Routine management
Number of subjects: 188
Study 32711724 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised haemodynamic management
Number of subjects: 188
Study 34533410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual oestradiol hemihydrate (1.3 mg/day) for 12 weeks
Number of subjects: 30
Study 34533410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34533410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual oestradiol hemihydrate (1.3 mg/day)
Number of subjects: 30
Study 35753879 — intervention group
Group type: EXPERIMENTAL
Intervention: TLH-CTM
Number of subjects: 60
Study 35753879 — intervention group
Group type: EXPERIMENTAL
Intervention: TAH-CTM
Number of subjects: 60
Study 35753879 — intervention group
Group type: COMPARATOR
Intervention: TLH control
Number of subjects: 60
Study 35753879 — intervention group
Group type: COMPARATOR
Intervention: TAH control
Number of subjects: 60
Study 33096222 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (short instructions alongside peer reviewers’ comments)
Number of subjects: 108
Study 33096222 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual peer-review process)
Number of subjects: 108
Study 32787416 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic education in CLP and CFD
Number of subjects: 123
Study 32787416 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional services offered by SLTs
Number of subjects: 123
Study 32787416 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for improvement in academic education
Number of subjects: 123
Study 32787416 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for educational improvement
Number of subjects: 123
Study 34502202 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shock wave therapy (LiESWT) at 0.25 mJ/mm2, 3000 pulses, 3 pulses/second
Number of subjects: 58
Study 34753612 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐directed web‐based stress management program (n = 30)
Number of subjects: 59
Study 34753612 — intervention group
Group type: EXPERIMENTAL
Intervention: web‐based stress management program plus lay telephone coaching (n = 29)
Number of subjects: 59
Study 34753612 — intervention group
Group type: COMPARATOR
Intervention: motivational interviewing (MI)
Number of subjects: 59
Study 32761276 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar denervation (PD)
Number of subjects: 202
Study 32761276 — intervention group
Group type: COMPARATOR
Intervention: Non-denervation group
Number of subjects: 202
Study 32448017 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic Resistance Training (IRT) for 12 weeks
Number of subjects: 90
Study 32448017 — intervention group
Group type: COMPARATOR
Intervention: Control group (CNG) - physically inactive during hemodialysis
Number of subjects: 90
Study 32326664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol 200 mg/day
Number of subjects: 51
Study 32326664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol 100 mg/day
Number of subjects: 51
Study 32326664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 32326664 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol (both doses)
Number of subjects: 51
Study 35737551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalcohol EFT conditions
Number of subjects: 360
Study 35737551 — intervention group
Group type: EXPERIMENTAL
Intervention: EFT content around professional work
Number of subjects: 360
Study 35737551 — intervention group
Group type: COMPARATOR
Intervention: Alcohol EFT conditions
Number of subjects: 360
Study 35737551 — intervention group
Group type: EXPERIMENTAL
Intervention: EFT valence
Number of subjects: 360
Study 35737551 — intervention group
Group type: EXPERIMENTAL
Intervention: EFT
Number of subjects: 360
Study 34444573 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary and physical activity interventions group (DPG; mobile phone with the App and bracelet)
Number of subjects: 750
Study 34444573 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity interventions group (PG; mobile phone with the App and bracelet)
Number of subjects: 750
Study 34444573 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; no interventions)
Number of subjects: 750
Study 32195903 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic version of the Pediatric Index of Mortality 2 score
Number of subjects: 12582
Study 32195903 — intervention group
Group type: COMPARATOR
Intervention: Manually ascertained Pediatric Index of Mortality 2 score
Number of subjects: 12582
Study 36001991 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual Angina (RA) at 1 year post-revascularization
Number of subjects: 1428
Study 36001991 — intervention group
Group type: COMPARATOR
Intervention: No Residual Angina (no-RA) at 1 year post-revascularization
Number of subjects: 1428
Study 34800398 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide (14 mg equivalent in adults)
Number of subjects: 166
Study 34800398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 34800398 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 166
Study 35709600 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg daily)
Number of subjects: 170
Study 35709600 — intervention group
Group type: COMPARATOR
Intervention: Abiraterone acetate plus prednisone (1000 mg abiraterone acetate and 10 mg prednisone daily)
Number of subjects: 170
Study 32947028 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminolevulinic acid/photodynamic therapy
Number of subjects: 269
Study 32947028 — intervention group
Group type: COMPARATOR
Intervention: Vehicle/photodynamic therapy
Number of subjects: 269
Study 33858390 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Hemodialysis (HD)
Number of subjects: 40
Study 33858390 — intervention group
Group type: EXPERIMENTAL
Intervention: HD with cooled dialysate
Number of subjects: 40
Study 33858390 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume HDF
Number of subjects: 40
Study 33858390 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume HDF (HV-HDF)
Number of subjects: 40
Study 33858390 — intervention group
Group type: EXPERIMENTAL
Intervention: All modalities
Number of subjects: 40
Study 33370247 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical oxygen continuously diffused to DFU tissue
Number of subjects: 0
Study 33370247 — intervention group
Group type: COMPARATOR
Intervention: Continuously diffused topical oxygen
Number of subjects: 0
Study 33370247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 0
Study 33175316 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% ophthalmic solution
Number of subjects: 59
Study 33175316 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears (control)
Number of subjects: 59
Study 34256588 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal bovine acellular dermal matrix (FBADM) plus standard of care (SOC)
Number of subjects: 207
Study 34256588 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 207
Study 33213440 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 42
Study 33213440 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocem MTA
Number of subjects: 42
Study 33213440 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 42
Study 34958762 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids plus hyaluronic acid (HA)
Number of subjects: 57
Study 34958762 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) alone
Number of subjects: 57
Study 34011181 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low level of symptoms on all outcomes
Number of subjects: 402
Study 34011181 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high psychotic symptoms
Number of subjects: 402
Study 34011181 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high anxio-depressive symptoms
Number of subjects: 402
Study 34011181 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated substance abuse and high levels of symptoms on all scales
Number of subjects: 402
Study 34011181 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood abuse (CA)
Number of subjects: 402
Study 34011181 — intervention group
Group type: EXPERIMENTAL
Intervention: Externalizing behaviors (EB)
Number of subjects: 402
Study 34011181 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 402
Study 34011181 — intervention group
Group type: COMPARATOR
Intervention: Comparison group of 92 healthy participants
Number of subjects: 402
Study 32051551 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary focal therapy (HIFU or cryotherapy)
Number of subjects: 0
Study 32051551 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine implementation of mpMRI
Number of subjects: 0
Study 35149036 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with edoxaban (a non-vitamin K antagonist oral anticoagulant)
Number of subjects: 1038
Study 35149036 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with edoxaban plus a single antiplatelet agent
Number of subjects: 1038
Study 32556194 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (5-day course)
Number of subjects: 58
Study 32556194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 34843839 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin administration
Number of subjects: 58
Study 34843839 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 58
Study 32330925 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT depletion
Number of subjects: 70
Study 32330925 — intervention group
Group type: EXPERIMENTAL
Intervention: DA depletion
Number of subjects: 70
Study 32330925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 36373820 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/day NWT-03
Number of subjects: 76
Study 36373820 — intervention group
Group type: COMPARATOR
Intervention: 5 g/day maltodextrin
Number of subjects: 76
Study 33537760 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation at 0.1 g · kg‐1 body weight · d‐1
Number of subjects: 132
Study 33537760 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein diet with placebo (control, CT)
Number of subjects: 132
Study 33537760 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet with placebo (HP)
Number of subjects: 132
Study 32515040 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe sterol
Number of subjects: 122
Study 32515040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 34348753 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral Neck System (FNS)
Number of subjects: 63
Study 34348753 — intervention group
Group type: COMPARATOR
Intervention: Triple Screw construct (TS)
Number of subjects: 63
Study 34348753 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Hip Screw system (DHS)
Number of subjects: 63
Study 35872150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension condition (instructed to increase sleep opportunity by 90 minutes)
Number of subjects: 72
Study 35872150 — intervention group
Group type: COMPARATOR
Intervention: Sleep as usual condition (control group)
Number of subjects: 72
Study 33988954 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder rotation position
Number of subjects: 40
Study 33988954 — intervention group
Group type: COMPARATOR
Intervention: Lateral decubitus position
Number of subjects: 40
Study 32128634 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (35 mg/m2 twice daily on days 1-5 and 8-12 of each 28-day cycle) plus best supportive care (BSC)
Number of subjects: 507
Study 32128634 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 507
Study 33837916 — intervention group
Group type: COMPARATOR
Intervention: Home sleep monitoring (H)
Number of subjects: 40
Study 33837916 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory sleep monitoring (L)
Number of subjects: 40
Study 32606078 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern Scanning Laser Trabeculoplasty (PSLT)
Number of subjects: 132
Study 32606078 — intervention group
Group type: COMPARATOR
Intervention: Selective Laser Trabeculoplasty (SLT)
Number of subjects: 132
Study 34346852 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) data from the Swedish national quality register (Q‐ECT)
Number of subjects: 200
Study 34637142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 2285
Study 34637142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2285
Study 36364794 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim milk (MILK)
Number of subjects: 13
Study 36364794 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate drink (CHO)
Number of subjects: 13
Study 32929647 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV therapy (interferon-based therapy or interferon-free therapy); duration of treatment not specified, but monitoring period is 6 months for cirrhosis patients and 3 months for non-cirrhosis patients.
Number of subjects: 0
Study 32929647 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV therapy (treated cohort)
Number of subjects: 0
Study 32929647 — intervention group
Group type: COMPARATOR
Intervention: Untreated cohort (therapy-naïve patients)
Number of subjects: 0
Study 32519327 — intervention group
Group type: EXPERIMENTAL
Intervention: Video presentation
Number of subjects: 37
Study 32519327 — intervention group
Group type: COMPARATOR
Intervention: Conventional educational leaflets and verbal instructions
Number of subjects: 37
Study 33798986 — intervention group
Group type: EXPERIMENTAL
Intervention: iLearning app for chest tube care
Number of subjects: 107
Study 33798986 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching
Number of subjects: 107
Study 33980397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (interpersonal communication)
Number of subjects: 3786
Study 33980397 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3786
Study 34968218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led complex intervention
Number of subjects: 63
Study 34968218 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 33848232 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-bOPV-bOPV
Number of subjects: 1200
Study 33848232 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-IPV-tOPV
Number of subjects: 1200
Study 33848232 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV-IPV-bOPV
Number of subjects: 1200
Study 33848232 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1200
Study 33848232 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sequential vaccination schedule of IPV and bOPV
Number of subjects: 1200
Study 33356044 — intervention group
Group type: EXPERIMENTAL
Intervention: Yihechun Capsules (YHC) + Levocarnitine (LC)
Number of subjects: 181
Study 33356044 — intervention group
Group type: COMPARATOR
Intervention: Levocarnitine (LC)
Number of subjects: 181
Study 33497514 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedling combined with NB‐UVB phototherapy and topical latanoprost 0.005%
Number of subjects: 50
Study 33497514 — intervention group
Group type: COMPARATOR
Intervention: Microneedling combined with NB‐UVB phototherapy
Number of subjects: 50
Study 36173222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LCD)
Number of subjects: 90
Study 36173222 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Fat Diet (LFD)
Number of subjects: 90
Study 36173222 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 90
Study 34146102 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase supplementation at 187.5 FYT/kg feed
Number of subjects: 90
Study 34146102 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase supplementation at 375 FYT/kg feed
Number of subjects: 90
Study 34146102 — intervention group
Group type: COMPARATOR
Intervention: Control diet (no phytase)
Number of subjects: 90
Study 36237565 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (omeprazole, amoxicillin, and clarithromycin) for 14 days
Number of subjects: 603
Study 36237565 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (omeprazole, amoxicillin, clarithromycin, and metronidazole) for 14 days
Number of subjects: 603
Study 33616000 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training group (n=22)
Number of subjects: 45
Study 33616000 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=23)
Number of subjects: 45
Study 34493289 — intervention group
Group type: EXPERIMENTAL
Intervention: Health warning
Number of subjects: 1235
Study 34493289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined health and environment warning
Number of subjects: 1235
Study 34493289 — intervention group
Group type: EXPERIMENTAL
Intervention: Environment warning
Number of subjects: 1235
Study 34493289 — intervention group
Group type: COMPARATOR
Intervention: No-label control
Number of subjects: 1235
Study 32406569 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop Drainage (LD)
Number of subjects: 238
Study 32406569 — intervention group
Group type: COMPARATOR
Intervention: Incision and Drainage (I&D)
Number of subjects: 238
Study 35416973 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose metronidazole 500 mg twice daily for 7 days
Number of subjects: 3700000
Study 35416973 — intervention group
Group type: COMPARATOR
Intervention: Single-dose oral metronidazole 2 g
Number of subjects: 3700000